Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Dorocubicel is a preparation of UM171-expanded cord-derived allogeneic HSCs used alongside unexpanded CD34-negative HSCs for the treatment of hematopoietic cancers in patients for whom other types of suitable donor cells are not available. Dorocubicel is a preparation of cryopreserved allogeneic umbilical cord-derived hematopoietic stem cells and blood progenitors expanded ex vivo using UM-171.
- Mechanism
- Curator reviewed · 4 references
The primary mechanism of action of dorocubicel involves the promotion of hematopoietic recovery and immune reconstitution through the activity of expanded CD34+ hematopoietic stem cells. Marketed as Zemcelpro, it is used in conjunction with unexpanded CD34- cells, primarily consisting of CD3+ T cells, which complement this action by supporting immune reconstitution and providing graft-versus-leukemia (GVL) effects post-transplantation.
Following transplantation, the hematopoietic stem/progenitor cells from Zemcelpro migrate to the bone marrow, where they divide, mature, and differentiate into all hematological cell lineages. The mature cells are then released into the bloodstream, circulating and migrating to tissue sites, partially or fully restoring blood counts and the function, including immune function, of blood-borne cells of marrow origin.
- Primary indication
- Dorocubicel is an active ingredient in Zemcelpro, a cryopreserved allogeneic hematopoietic stem and progenitor cell therapy indicated for the treatment of adult patients with hematological malignancies requiring an allogeneic hematopoietic stem cell transplantation following myeloablative...Curator reviewed · 1 structured indication
- Also known as
- Allogeneic human umbilical cord blood expanded with UM-171
- Code names
- ECT-001-CB-DP1
Resolves to
What you can answer from here — as of October 21, 2025
Which other approved drugs treat the same conditions as Dorocubicel, and which companies have late-stage candidates in those indications?